STOCK TITAN

Passage Bio, Inc. - $PASG STOCK NEWS

Welcome to our dedicated page for Passage Bio news (Ticker: $PASG), a resource for investors and traders seeking the latest updates and insights on Passage Bio stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Passage Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Passage Bio's position in the market.

Rhea-AI Summary
Passage Bio's CEO to participate in fireside chat at Chardan's Genetic Medicines Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.11%
Tags
-
Rhea-AI Summary
Passage Bio announces new interim safety, biomarker, and survival data from the Imagine-1 clinical study. Dose 2 of PBGM01 shows substantial improvements in CSF biomarkers and achieves normal levels of CSF β-Gal activity and GM1 gangliosides. Initial evidence of improved survival relative to natural history data. Dose 3 data expected by mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.11%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
conferences
-
Rhea-AI Summary
Passage Bio, Inc. (Nasdaq: PASG) announces the appointment of Dr. Dolan Sondhi to the Board of Directors and her role in the Nominating and Corporate Governance Committee. Dr. Sondhi brings extensive experience in AAV gene therapy research and neurodegenerative diseases, aligning with Passage Bio's mission to develop transformative therapies for CNS disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.49%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.91%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.87%
Tags
conferences
Passage Bio, Inc.

Nasdaq:PASG

PASG Rankings

PASG Stock Data

80.71M
37.41M
0.32%
55.75%
2.38%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
PHILADELPHIA

About PASG

passage bio, inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (cns) diseases. the company develops pbgm01, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional glb1 gene encoding lysosomal acid beta-galactosidase (ãŸ-gal) for infantile gm1; pbft02, which utilizes an aav1 capsid to deliver to the brain a functional granulin, or grn, gene encoding progranulin for the treatment of ftd caused by a deficiency of progranulin; and pbkr03, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional galc gene encoding the hydrolytic enzyme galactosylceramidase, for infantile krabbe disease. it has a strategic research collaboration with the trustees of the university of pennsylvania's gene therapy program; and collaboration agreement, and a development services and clinical supply agreement with catalent maryland, inc. the company was fou